Tag: pubmed

J Cancer Res Ther. 2024 Apr 1;20(2):592-598. doi: 10.4103/jcrt.jcrt_1627_23. Epub 2024 Apr 30.

ABSTRACT

OBJECTIVE: To analyze the characteristics of retracted oncology papers from Chinese scholars and the reasons for retraction.

METHODS: Data on retracted oncology papers from Chinese scholars published from 2013 to 2022 were retrieved from the Retraction Watch database. The retraction number and annual distribution, article types, reasons for retraction, retraction time delay, publishers, and journal characteristics of the retracted papers were analyzed.

RESULTS: A total of 2695 oncology papers from Chinese scholars published from 2013 to 2022 had been retracted. The majority of these papers were published from 2017 to 2020. In terms of article type, 2538 of the retracted papers were research articles, accounting for 94.17% of the total number of retracted papers. The main reasons for retraction were data, result, and image problems, duplicate publication, paper mills, author- and third-party-related reasons, plagiarism, false reviews, and method errors. The retraction time delay for the retracted papers ranged from 0 to 3582 days (median, 826 days). The retractions mainly occurred within the first 4 years after publication. A total of 77 publishers were involved in the retracted papers. In terms of journal distribution, 394 journals were involved in the retracted papers, of which 368 (93.40%) were included in the SCI database. There were 243 journals with an impact factor of <5 (66.03%).

CONCLUSION: In the field of oncology, the annual distribution of retracted papers from Chinese scholars exhibited first an increasing and subsequently a decreasing trend, reaching a peak in 2019, indicating an improvement in the status of retraction after 2021. The main type of the retracted papers was research article, and the main reason for retraction was academic misconduct. The retractions were mainly concentrated in several major publishers and periodicals in Europe and the United States. Most of the journals had low-impact factors.

PMID:38687929 | DOI:10.4103/jcrt.jcrt_1627_23

J Cancer Res Ther. 2024 Apr 1;20(2):555-562. doi: 10.4103/jcrt.jcrt_750_22. Epub 2023 Apr 5.

ABSTRACT

INTRODUCTION: There are emerging but inconsistent evidences about anti-epileptic drugs (AEDs) as radio- or chemo-sensitizers to improve survival in glioblastoma patients. We conducted a nationwide population-based study to evaluate the impact of concurrent AED during post-operative chemo-radiotherapy on outcome.

MATERIAL AND METHODS: A total of 1057 glioblastoma patients were identified by National Health Insurance Research Database and Cancer Registry in 2008-2015. Eligible criteria included those receiving surgery, adjuvant radiotherapy and temozolomide, and without other cancer diagnoses. Survival between patients taking concurrent AED for 14 days or more during chemo-radiotherapy (AED group) and those who did not (non-AED group) were compared, and subgroup analyses for those with valproic acid (VPA), levetiracetam (LEV), or phenytoin were performed. Multivariate analyses were used to adjust for confounding factors.

RESULTS: There were 642 patients in the AED group, whereas 415 in the non-AED group. The demographic data was balanced except trend of more patients in the AED group had previous drug history of AEDs (22.6% vs. 18%, P 0.078). Overall, the AED group had significantly increased risk of mortality (HR = 1.18, P 0.016) compared to the non-AED group. Besides, an adverse dose-dependent relationship on survival was also demonstrated in the AED group (HR = 1.118, P 0.0003). In subgroup analyses, the significant detrimental effect was demonstrated in VPA group (HR = 1.29,P 0.0002), but not in LEV (HR = 1.18, P 0.079) and phenytoin (HR = 0.98, P 0.862).

CONCLUSIONS: Improved survival was not observed in patients with concurrent AEDs during chemo-radiotherapy. Our real-world data did not support prophylactic use of AEDs for glioblastoma patients.

PMID:38687925 | DOI:10.4103/jcrt.jcrt_750_22

J Cancer Res Ther. 2024 Apr 1;20(2):547-554. doi: 10.4103/jcrt.jcrt_1246_23. Epub 2024 Apr 30.

ABSTRACT

OBJECTIVE: To investigate the safety and short- and long-term efficacy of ultrasound-guided microwave ablation (MWA) with parallel acupuncture for treating single hepatocellular carcinoma (HCC) in high-risk areas.

METHODS: Retrospective analysis was performed on 155 patients with single hepatocellular carcinoma who underwent microwave ablation in our hospital between December 2015 and September 2016. Patients with a tumor distance of ≤5 mm from the risk area were included in the observation group. Patients with a tumor distance of >5 mm from the risk area were placed in the control group. The patients’ preoperative general health status, tumor site, tumor size, follow-up data, disease-free survival rate, overall survival rates, local tumor progression, and intrahepatic distant recurrence rate were collected and analyzed.

RESULTS: The 1-, 3-, and 5-year overall survival rates for the observation group were 91.8%, 75.5%, and 59.2%, respectively. The 1-, 3-, and 5-year overall survival rates for the control group were 97.2%, 84.0%, and 66.0%, respectively. There were no significant differences between the two groups (P = 0.522). A tumor size of ≤20 mm (HR = 0.488, 95% CI = 0.254-0.940, P = 0.032) was an independent risk factor affecting the overall survival of patients with solitary HCC treated with MWA. The 1-, 3-, and 5-year recurrence-free survival rates for the observation group were 59.2%, 28.6%, and 18.4%, respectively, and those for the control group were 79.2%, 43.4%, and 31.1%, respectively. There was a statistical difference between the two groups (P = 0.007). Tumor size ≤20 mm (HR = 0.468, 95% CI = 0.303-0.723, P = 0.001), tumor location in a risk area (HR = 1.662, 95% CI = 1.121-2.465, P = 0.011), and an α-fetoprotein (AFP) level of <200 ug/L (HR = 0.612, 95% CI = 0.386-0.970, P = 0.036) are independent factors affecting the recurrence-free survival of MWA treatment for HCC.

CONCLUSION: Microwave ablation with parallel acupuncture guided by ultrasound is a safe and effective treatment for single hepatocellular carcinoma in high-risk areas.

PMID:38687924 | DOI:10.4103/jcrt.jcrt_1246_23

J Cancer Res Ther. 2024 Apr 1;20(2):509-521. doi: 10.4103/jcrt.jcrt_1031_23. Epub 2024 Apr 30.

ABSTRACT

The incidence of thromboembolic events (TEs) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) has rarely been reported. The MEDLINE, EMBASE, and the Cochrane Library databases were searched. The primary outcome was the incidence of TEs, and the secondary outcome was the relationship between TEs and overall survival (OS) following ICI therapy. A subgroup analysis of TE incidents was performed according to the TE type and combination regimens. The I2 statistic was used to determine the heterogeneity, and funnel plots and Egger’s test were used to assess publication bias. A total of 16,602 patients with NSCLC in 63 experimental arms were included in the analysis. The rate of TEs ranged from 0.1% to 13.8%, and the pooled overall incidence of all-grade TEs was 3% (95% confidence interval [CI], 2%-4%). The pooled rate of high-grade TEs was 1% (95% CI, 1%-2%). The venous and arterial TE rates were 3% (95% CI, 2%-4%) and 1% (95% CI, 1%-2%), respectively. Patients who received immunotherapy + chemoradiotherapy had the highest incidence of TEs (7%). The TE pooled rate was higher in patients treated with combined ICIs than in those treated with mono ICIs (4% vs. 2%). The OS was lower in patients with TEs than in those without TEs (hazard ratio, 1.4; 95% CI, 1.02%-1.92%). The incidence of TEs in NSCLC patients treated with ICIs was reasonable. Nonetheless, clinicians must be aware of potential thrombotic complications and treat them promptly.

PMID:38687920 | DOI:10.4103/jcrt.jcrt_1031_23

Altern Ther Health Med. 2024 Apr 26:AT9713. Online ahead of print.

ABSTRACT

OBJECTIVE: The current study aimed to analyze the postoperative intracranial infection in patients with senile cerebral tumors treated by craniotomy.

METHODS: This retrospective study included 116 patients with senile cranial tumors admitted and treated in our Hospital from January 2019 to January 2021. The patients were assigned to an observation group and a conventional group, by different nursing interventions, with 58 patients in each. Patients in both groups were treated with craniotomy, in which patients in the conventional group were given routine nursing. In contrast, patients in the observation group were provided with predictive nursing interventions. Predictive nursing interventions encompass personalized care plans, early identification of infection risk factors, and tailored prophylactic measures. A comparative analysis of the nursing intervention effect, self-management of the patients, and impact on the physical and mental health of the patients was performed between the two groups, with statistical significance set at P < .05. The Short Form Health Survey (SF-36) is a widely used and well-validated questionnaire designed to measure health-related quality of life and is adopted in this study to assess the quality of life of patients.

RESULTS: The number of intracranial infection cases in the observation group (4) was significantly less than in the conventional group (14), and the incidence of intracranial infection in the observation group (6.90%) was significantly reduced than in the conventional group (24.14%) (P < .05). Moreover, the effective rate of patients in the observation group (96.55%) was significantly higher than that in the conventional group (77.59%) (P < .05). The quality of life of patients in both groups improved, and the SF-36 score of patients in the observation group (70.25±7.18) was significantly higher than that of the conventional group (60.18±5.54) (P < .05). The total satisfaction of patients in the observation group (98.28%) was significantly higher than that of the conventional group (82.76%) (P < .05). Predictive nursing interventions minimize the incidence of postoperative complications, particularly intracranial infections, leading to improved treatment outcomes, enhanced quality of life, and increased patient satisfaction.

CONCLUSION: The provision of predictive nursing care to patients with senile cranial tumors treated with craniotomy can effectively reduce the incidence of postoperative intracranial infection, and the nursing effect is better for patients with or without intracranial infection, which can significantly contribute to the quality of life quality improvement and effectively enhance patients’ satisfaction. Further research is imperative to evaluate and promote the practice as a significant toolkit in clinical practice. Future investigations should focus on the enduring impact of predictive nursing interventions in senile cerebral tumor patients post-craniotomy, unraveling sustained benefits over an extended period. The study’s findings underscore the potential for transformative nursing practices in craniotomy for senile cranial tumors, advocating for the integration of predictive nursing interventions to enhance patient safety, satisfaction, and overall well-being.

PMID:38687866

Altern Ther Health Med. 2024 Apr 26:AT10366. Online ahead of print.

ABSTRACT

OBJECTIVE: Myocardial infarction, coronary heart disease is one of the serious types, come on urgent, case fatality rate is high, especially the front wall or extensive anterior wall myocardial infarction, easy to merge cardiac insufficiency, arrhythmia, even in patients with sudden death will happen, and life-threatening. The aim of this study was to investigate the effects of HOPE management mode on cardiac function, quality of life and in-hospital cardiovascular adverse events in patients with myocardial infarction.

METHODS: 118 patients with myocardial infarction hospitalized in our hospital from January 2020 to March 2022 were randomly divided into study group (n=59) and control group (n=59) and carried out a prospective study. The study group was treated with HOPE management mode, the control group was treated with conventional intervention. The LVEF, GRACE, quality of life were evaluated before intervention, 1 week after, 1 month and 3 months after intervention to evaluate the improvement of clinical symptoms, cardiac function and quality of life of patients.

RESULTS: The LVEF were increased from (42.94±2.38) % to (47.03±2.62) % in control group and from (43.51±2.45) to (52.94±3.09) in sudy group; the quality of life were increased from (42.08±7.44) points to (57.00±4.49) points in control group and (43.76±6.68) points to (69.42±8.03) points in sudy group; the GRACE score were increased from (152.10±14.52) points to (110.10±9.73) points in control group and (153.63±15.11) points to (81.71±10.21) points in sudy group, the difference were statistically significant (P < .05). All indicators in study group were better than those in control group at each time point after intervention (P < .05). Kaplan-Meier curve showed that the incidence of adverse cardiovascular events in the study group was lower than that in the control group within 3 months. Within 90 days of hospitalization, the incidence of adverse cardiovascular events were 28.81% in the control group, which was higher than 15.25% in the study group (P < .05). Kaplan-meier observation showed that the incidence of adverse cardiovascular events in control group was significantly higher than that in study group (χ2=5.586, P = .018).

CONCLUSIONS: The HOPE management model can effectively improve the cardiac function and quality of life of patients with myocardial infarction, and reduce GRACE scores and the incidence of in-hospital cardiovascular adverse events, which can as a comprehensive approach to improve clinical outcomes and enhance the quality of life for patients with myocardial infarction.

PMID:38687863

Altern Ther Health Med. 2024 Apr 26:AT9627. Online ahead of print.

ABSTRACT

OBJECTIVE: The study aims to assess and compare the outcomes of modified radical surgery, preserving the nipple-areola complex, against radical mastectomy in patients with triple-negative breast cancer. Emphasis is placed on the clinical significance of this comparison, including its potential impact on patient outcomes, quality of life, and healthcare resources.

METHODS: Relevant literature from January 2017 to January 2022 was searched in the following databases: PubMed, Embase, MEDLINE, Science Citation Index, Web of Science, China National Knowledge Internet, CCD, and CSPD with keywords. The electric search yielded 613 relevant articles, including 351 from Pubmed, 187 from Embase, 5 from MEDLINE, 21 from CNKI, 4 from CCD, and 45 from CSPD. After duplicate screening, 185 items were eliminated, leaving 428 articles. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated with RevMan 5.3, and sensitivity analysis, cumulative meta-analysis, and publication bias analysis were also performed. A total of 613 relevant articles were collected from the above databases, among which 428 articles remained after the initial screening and were further screened based on the established inclusion and exclusion criteria. The efficacy of modified radical surgery and breast-conserving surgery in the treatment of early breast cancer was assessed by analyzing outcome indicators, including recurrence rate, distant metastatic rate, and three-year survival rate. The methods section details a systematic approach to data collection and analysis, specifying the databases and time frame for the literature search and the statistical tools used for the meta-analysis. The selection process, from the initial number of articles to the final inclusion based on defined criteria, is transparent, ensuring the study’s methodological robustness in evaluating the efficacy of surgeries for early breast cancer.

RESULTS: Finally, ten articles were found to match the criteria and included in this study. According to the meta-analysis, there was no statistically significant difference between the breast-conserving therapy (BCT) and modified radical mastectomy (MRM) groups in terms of the recurrence rate (OR = 0.76, 95%CI = 0.39, 1.55, P > .05) and distant metastatic rate (OR = 0.81, 95%CI = 0.46, 1.31, P > .05). Nevertheless, the three-year survival rate was 85.2% in the BCT group and 91.7% in the MRM group; a statistically significant difference was observed in the three-year survival rate (OR = 1.47, 95%CI = 1.01, 2.37, P = .03) between the BCT and MRM groups. Accordingly, breast-conserving surgery and modified radical surgery produced comparable clinical outcomes for the treatment of early breast cancer.

CONCLUSION: In the treatment of early breast cancer, breast-conserving surgery has the advantages of less bleeding, fewer clinical complications, and favorable cosmetic outcomes compared with modified radical surgery. Furthermore, patients with breast-conserving surgery showed comparable recurrence and distant metastatic rates to those with modified radical surgery in postoperative follow-up, which, therefore is a suitable treatment option for the widespread recommendation. The study’s findings hold significant clinical relevance, implying that while BCT remains a viable option, MRM may offer a survival advantage. This insight empowers both patients and clinicians in making informed, personalized treatment decisions tailored to individual circumstances.

PMID:38687862

Altern Ther Health Med. 2024 Apr 26:AT10043. Online ahead of print.

ABSTRACT

OBJECTIVE: This meta-analysis aims to evaluate the comparative clinical efficacy of photodynamic therapy (PDT) versus other non-surgical treatments in managing peri-implantitis.

METHODS: Computer searches were conducted in databases including PubMed, The Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang for randomized controlled trials (RCTs) on the clinical efficacy of Photodynamic Therapy (PDT) compared to other non-surgical methods in the treatment of peri-implantitis. The search period spanned from May 2000 to May 2023. Based on inclusion and exclusion criteria, literature was screened, data extracted, and the quality of the studies was assessed. Included studies were publicly published randomized controlled experiments focusing on the combination of photodynamic therapy and non-surgical methods compared to non-surgical methods alone in the treatment of peri-implantitis. Articles with insufficient or unclear definitions of peri-implantitis cases were excluded from the selected studies. Statistical analysis was performed using RevMan 5.3 software.

RESULTS: Nine RCTs were included for Meta-analysis. Meta-analysis showed that patients in the PDT trial group had reduced peri-implant probing depth (PD) during the follow-up period compared with the control group [WMD=-0.40, 95%CI(-0.62,-0.17), P = .0005], and bleeding on probing (BOP) was reduced [WMD=-9.20, 95%CI(-13.69,-4.71), P < .0001] more significantly, and the difference between the two groups was statistically significant (P < .05); while for Modified plaque index (mPI) decreased [MD=-0.07, 95%CI (-0.16, 0.01), P = .09], clinical attachment loss (CAL) gained [WMD=-0.66, 95%CI:(-1.46, 0.14), P = .11]. Plaque index (PI%) decreased [WMD=-1.66, 95%CI:(-3.43, 0.11), P = .07] insignificantly, and the difference between the two groups was not statistically significant (P > .05).Photodynamic Therapy (PDT) has been significantly effective in reducing periodontal pocket depth and gingival bleeding in the treatment of periodontal diseases. However, its efficacy in improving plaque control and promoting tooth attachment is limited, which may be attributed to its primary antibacterial action rather than promoting tissue repair.

CONCLUSION: Compared to other non-surgical treatments, PDT treatment has significant advantages in reducing peri-implant probing depth and bleeding in patients with peri-implantitis. These results suggest that PDT may be a more effective non-surgical option for reducing probing depth and bleeding in patients with peri-implantitis. Of course, future studies with larger sample sizes and longer follow-up periods are needed to confirm these findings.

PMID:38687855

Altern Ther Health Med. 2024 Apr 26:AT9031. Online ahead of print.

ABSTRACT

OBJECTIVE: Deep venous thrombosis (DVT) refers to a clot in a deep vein caused by various reasons. If such a clot becomes dislodged, it can return to the vein and lead to pulmonary embolism (PE), which can cause death in severe cases. Therefore, we aimed to evaluate the efficacy and safety of Safflower yellow combined with low molecular weight heparin (LMWH) for the prevention of DVT after orthopedic surgery.

METHODS: A comprehensive search of randomized controlled studies (RCTs) of Safflower yellow combined with LMWH for the prevention of DVT after orthopedic surgery was performed in PubMed, Embase, Cochrane Library, CNKI, VIP, and Wanfang databases from January 2000 to June 2021. Data were extracted for quality evaluation and meta-analysis was performed using RevMan 5.3 software.

RESULTS: A total of 8 RCTs including 624 patients were included. The combination treatment reduced the incidence of DVT compared with the control group; the combination treatment improved the activated partial thromboplastin time (APTT) and prothrombin time (PT). There was no statistically significant difference in the incidence of adverse effects.

CONCLUSION: Safflower yellow combined with LMWH can reduce postoperative blood hypercoagulability and prevent DVT formation in lower extremities in orthopedic patients, and achieves better outcomes than LMWH alone in terms of postoperative bleeding tendency.

PMID:38687854

Altern Ther Health Med. 2024 Apr 26:AT10368. Online ahead of print.

ABSTRACT

OBJECTIVE: This study aims to elucidate the significance of HOX11 gene expression in acute leukemia, offering insights for readers unfamiliar with this gene’s role.

METHODS: We utilized qRT-PCR to examine HOX11 expression in 76 patients, categorizing them into high and low expression groups based on specific thresholds established for this study. Real-time quantitative polymerase chain reaction (qRT-PCR) was performed at the time of diagnosis and on day 28, associated with the analysis of the correlation of HOX11 gene expression with clinical outcomes and prognosis.

RESULTS: On days 0 and 28, the median HOX11 gene expression in patients with acute myeloid leukemia (AML) was 16.2 and 4.43, respectively, which was 9.67 and 2.37 in patients with acute lymphocytic leukemia (ALL), respectively. Enrolled patients were further divided into high genome and low expression groups based on the expression of HOX11. The median HOX11 gene expression on days 0 and 28 in nonresponders to therapy was significantly higher than that in responders to therapy. In addition, baseline HOX11 gene expression was significantly lower in patients with complete remission than in patients with recurrence. The high expression of the HOX11 gene was associated with shorter overall survival time and disease-free survival time. Our findings reveal significant differences in HOX11 expression between patient groups and across time points, suggesting implications for patient prognosis. The results consistently highlight statistically significant differences, enhancing the study’s validity.

CONCLUSION: The study suggests the potential of using HOX11 expression as a marker in clinical practice for monitoring acute leukemia prognosis.

PMID:38687853